Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02784002 · ClinicalTrials.gov registry record · Phase 2
A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
A Phase 2 study, sponsored by Summit Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT02784002 is a Phase 2 study that has completed, run by Summit Therapeutics. The registered enrollment target is 27 participants.
The verdict
NCT02784002, a Phase 2 study, has completed, sponsored by Summit Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the safety and effectiveness of Ridinilazole (SMT19969) in treating C. difficile Infection (CDI).
Interventions
- DRUG Fidaxomicin
- DRUG Ridinilazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02784002
The ClinicalTrials.gov registry entry for NCT02784002 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Summit Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fidaxomicin is the first listed.
NCT02784002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02784002 about?
NCT02784002 is a clinical study titled "A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)". The purpose of this research study is to evaluate the safety and effectiveness of Ridinilazole (SMT19969) in treating C. difficile Infection (CDI).
What is the current status of trial NCT02784002?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2014-12. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02784002?
The interventions under investigation include: Fidaxomicin (DRUG), Ridinilazole (DRUG).
Who is sponsoring clinical trial NCT02784002?
This trial is sponsored by Summit Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.